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Abstract
Despite three decades of promise, a neuro-imaging biomarker capable of delineating the ischemic 
penumbra is yet to be definitively demonstrated. Much progress has been made, especially with 
MR imaging. However, in order to rigorously define an imaging biomarker of the ischemic 
penumbra, carefully designed studies which can derive ischemic thresholds using quantitative 
imaging parameters may be required. Two thresholds are of interest: one which distinguishes the 
ischemic core from penumbra, and another which distinguishes the penumbra from benign 
oligemia. In this review, we discuss one possible approach to define these thresholds by following 
tissue fate in the presence or absence of early reperfusion.
The ischemic penumbra: from concept to clinical practice
The concept of the “ischemic penumbra,” first coined by Astrup in 1977, was based on 
almost a decade of research in a variety of gyrencephalic animal models of focal cerebral 
ischemia. These studies revealed two cerebral blood flow (CBF) thresholds of ischemia: an 
upper threshold which defined electrical failure in brain tissue, encompassing 
functionallyimpaired but structurally-intact neurons (which corresponded to a CBF of 15ml/
100g/min); and a lower threshold below which intracellular potassium was released into the 
extracellular space, which was believed to represent functional and structural impairment 
(corresponding to 6ml/100g/min) 1–3. Astrup posed that the penumbra represented tissue 
between these two thresholds, including “areas with less severe ischemia…with electrical 
failure but sustained energy metabolism and low extracellular potassium and with the 
possible potential for recovery”, in contrast to the ischemic core which he described as 
“areas of severe ischemia with energy failure, high extracellular potassium, and developing 
infarction” 4. This technical definition of penumbra was later generalized and rewritten as “a 
zone of nonfunctioning but still viable tissue that may recover its function if blood flow can 
be restored, for example, by therapeutic intervention.” 5, and has been widely accepted 
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today. Critical to this definition was the concept that ischemic brain tissue could be impaired 
but viable—as evidenced by subsequent survival of tissue after reperfusion. Also important 
was the concept that time was a critical component of viability. While reperfusion that 
occurred within a window of tissue viability could rescue brain tissue from death, 
reperfusion that occurred too late was ineffective for tissue survival.
Ultimate proof for the existence of the ischemic penumbra in human stroke came from 
clinical trials of reperfusion-promoting therapies demonstrating clinical benefit in patients 
treated with thrombolytic therapy (intravenous recombinant tissue plasminogen activator 
[tPA] and intra-arterial recombinant pro-urokinase)6–8. Thus, brain tissue that would have 
died without reperfusion was salvaged after thrombolysis, reflected by improved clinical 
outcome. Aggregate data from multiple thrombolytic trials also demonstrated a clear 
relationship between time interval from symptom onset to tPA treatment, and long-term 
clinical outcome 9. In stroke populations, these studies suggest a relatively short time 
window for tissue salvage—intravenous and intra-arterial thrombolysis have demonstrated 
benefit only up to 4.5 hours and 6 hours after symptom onset, respectively 6–8, with 
diminishing efficacy for longer time intervals.
While the above definition of “ischemic penumbra” is based on tissue salvage in response to 
adequate and timely reperfusion, there is substantial evidence in animal models (but not 
humans) that brain tissue can be rescued from infarction using neuroprotective interventions 
independent of reperfusion10. These interventions aim to alter a variety of biochemical 
pathways involved in neural cells death cascades—each defining a different “penumbra”. 
Therefore, it has been suggested that a more appropriate term might be “preventable 
infarction” 11 in which tissue within regions of preventable infarction will die if untreated 
and will live if treated. Such a term encompasses tissue that may be salvaged by any 
therapy, not just reperfusion-promoting therapy. However, for the purposes of this article, 
we have focused on identification of tissue which will be salvaged by tissue reperfusion, 
thus utilizing the original term, “ischemic penumbra”.
Imaging the ischemic penumbra
Not long after the concept of the ischemic penumbra was conceived, several imaging 
methods were applied to acute ischemic stroke patients in attempt to delineate salvageable 
tissue. Early studies utilizing positron emission tomography (PET) revealed that CBF 
thresholds for brain function and tissue death were similar to those found in primates stroke 
models 12–14. Moreover, a unique pattern of hemodynamic and metabolic change emerged 
during early phases of ischemia: reduced CBF associated with increased oxygen extraction 
fraction (OEF, the fraction of oxygen extracted from arterial blood) with preserved oxygen 
consumption (CMRO2). This state was termed “misery perfusion” and was postulated to be 
a PET imaging signature of the ischemic penumbra 15. The hallmark of this state was an 
increase in OEF in regions of low blood flow, resulting in a preservation of CMRO2. 
Follow-up PET imaging demonstrated a dramatic decrease in OEF in some of these regions 
(with concomitant decline in CMRO2), suggesting tissue progression to infarction 16, 
confirmed by longer-term imaging with CT. Brain tissue with CMRO2 below a certain 
threshold value was thought to represent the lower limit of the penumbra. Performing 
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transient MCA occlusion in anesthetized baboons, Touzani et al. 17 concluded that CMRO2 
< 40% of the contralateral hemisphere predicted tissue with eventual infarction. Powers et 
al. 14 measured regional CBF and CMRO2 in 50 patients with varying degrees of cerebral 
ischemia and established a minimum CMRO2 of 1.3 ml/100g/min for maintaining brain 
viability, corresponding to 37–39% of normal values 18. Importantly, unlike the CBF 
thresholds determined in earlier animal studies, CMRO2 thresholds were thought to be 
independent of the time interval after stroke onset making it an ideal marker for 
identification of viable tissue in ischemic stroke patients19. However, such PET-derived 
markers are largely based on controlled primate MCA occlusion-reperfusion experiments; 
reperfusion studies in humans have not been performed, thus prohibiting any definitive 
statements about PET’s ability to delineate the penumbra in humans.
More recent PET studies have evaluated potential biomarkers for delineating the ischemic 
core. In particular, 11C-flumazenil (FMZ) binding to cerebral GABA receptors does not 
require arterial blood sampling as does calculation of CMRO2, which are known to be 
sensitive to ischemia and neuronal loss, has been examined following transient MCA 
occlusion experiments in cats 20. Increased FMZ-binding correlated well with CMRO2 
values for irreversible injury as well as the final infarction. In ischemic stroke patients, 
FMZ-binding also demonstrated moderate sensitivity and good specificity for infarcted 
tissue 21, 22. Similar to other PET markers, these studies have not assessed how FMZ-
binding may predict tissue infarction in reperfused compared to non-reperfused tissue in 
humans within a clinically-relevant time window, thus its potential as a penumbral marker is 
currently unclear.
In many ways, the ideal quantitative physiological imaging measures provided by PET have 
been clinically limited by logistical hurdles of utilizing this technology in hyper-acute 
ischemic stroke patients. Around the clock availability of short-lived isotopes, limited 
availability in specialized centers, and requirement for arterial lines, have limited PET 
studies in the hyperacute setting of stroke. Thus, alternative MR and CT imaging approaches 
have been extensively explored. Multi-modal MRI has shown tremendous promise. 
Diffusion weighted imaging (DWI) has been used to delineate irreversibly-injured tissue 
(i.e. the ischemic core) and perfusion weighted imaging (PWI) for delineating the extent of 
critically hypoperfused tissue that will evolve into infarction if not reperfused in a timely 
manner. When DWI and PWI are combined together, the non-overlapping region depicted 
by DWI and PWI (mismatch) is postulated to represent the penumbra 23–25. Consistent with 
the idea of an evolving ischemic core, Baird et al. 26 and others demonstrated growth of the 
DWI lesion into a final infarct approximating the early PWI abnormality. However, studies 
have demonstrated that DWI lesions can reverse after reperfusion with subsequent tissue 
survival, suggesting that DWI lesions may not accurately represent the ischemic core 27, 28; 
moreover, studies have suggested that the territory delineated by PWI abnormalities may 
overestimate the penumbra29. Regardless, the methodology has been rapidly translated into 
several human studies, demonstrating the potential clinical utility of DWI-PWI mismatch for 
selection of patients beyond the therapeutic window 23–25.
Like MR, CT perfusion has become more widely available. Wintermark et al. 30 identified a 
relative CBF of <34% of the contralateral hemisphere for delineating tissue that died in the 
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absence of reperfusion, but survived if reperfused. In one prospective multi-center study, 
acute ischemic stroke patients were imaged < 12 hours from stroke onset with CT and 
MRI 31. The perfusion CT parameter most accurately reflecting the ischemic core (as 
compared to DWI) was absolute cerebral blood volume (CBV) < 2 ml/100g, while the 
parameter most accurately reflecting the penumbra was a relative mean transit time > 145% 
of the contralateral hemisphere. However, in more recent studies, relative CBF was found to 
be more predictive of the ischemic core and final infarct volume than absolute CBV 32–34. In 
contrast to MR with its measurement of DWI, CT does not have as specific a marker of the 
ischemic core and therefore has not been translated into clinical studies as readily as MR.
While structural- and blood flow-based imaging markers of the penumbra have been a large 
focus of recent studies aimed at identifying salvageable tissue, an ideal marker of tissue 
viability would measure to what degree the metabolic demands of the tissue are being met. 
The putative time-invariance of the CMRO2 threshold make it a potentially attractive index 
to define injury thresholds, unlike that of CBF which is time-dependent. To date, however, 
confirmation of tissue viability in regions of elevated OEF or confirmation of definite tissue 
infarction in regions of low CMRO2 in hyper-acute ischemic stroke populations have not 
been possible due to the aforementioned practical limitations when attempting to image 
hyper-acute stroke patients with PET. Therefore, several investigations are ongoing in 
attempt to measure oxygen metabolism using MRI (MR-OMI, magnetic resonance-oxygen 
metabolic index) by taking advantage of the endogenous susceptibility of deoxyhemoglobin 
on T2* weighted images, in addition to several other novel methods 35–37.
Several imaging modalities and quantitative imaging parameters have been explored as 
potential biomarkers for defining the ischemic penumbra. Some of these parameters quantify 
physiological parameters (perfusion-related parameters, metabolism, etc), while others are 
empirically-derived (DWI). To take full advantage of the quantitative nature of the imaging 
parameters and how they may best predict eventual tissue fate, ideally, systematic methods 
will be used to define ischemic thresholds (for defining the upper and lower limit of the 
penumbra) prior to testing in clinical trials.
Defining the penumbra using reperfusion analysis
A major challenge for defining the penumbra using non-invasive imaging is the uncertainty 
of tissue fate in this brain region during hyperacute ischemia. To define the penumbra (tissue 
that will be salvaged from reperfusion), brain tissue that is already destined to die (core) 
must be distinguished from tissue that may survive if reperfused (penumbra), which must 
also be distinguished from tissue that is not at risk of dying (benign oligemia). Two 
thresholds are relevant in defining the penumbra: one which distinguishes core from 
penumbra, and a second which distinguishes penumbra from oligemia.
One hurdle in defining the ischemic core is that there is no imaging biomarker for brain 
tissue death (that is apparent immediately)—brain tissue that is fated to die usually takes 
many hours to reveal characteristic features of death (T2 or FLAIR signal). As discussed 
above, MR DWI appears within 30 min of ischemia and approximates the core, but evidence 
suggests that diffusion lesions are reversible with reperfusion, and when this occurs, heralds 
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better tissue survival rates than persistent diffusion lesions 27. Thus, DWI may not be a 
reliable biomarker of the ischemic core. Therefore, another approach is needed whereby 
eventual tissue infarction can be correlated with early imaging characteristics that predict 
eventual tissue fate. This can be accomplished by co-registering hyperacute images with 
later time-point images (for example at 1 or 3 months) to determine which tissue eventually 
dies or survives, on a voxel-by-voxel basis.
In his original definition of penumbra, Astrup refers to “a zone of nonfunctioning but still 
viable tissue that may recover its function if blood flow can be restored.” Therefore, 
reperfusion is a critical component for defining the penumbra, which is encompassed by the 
two thresholds described above. However, defining reperfusion at the tissue level requires 
imaging at two timepoints: one at baseline, and a second at a later time-point to define which 
tissue reperfused. Critically important is the choice of time-point for the 2nd image, as 
reperfusion may alter tissue outcome only if it occurs within a time-window of tissue 
viability. Thus, “effective reperfusion” must occur within this time window, in contrast to 
“ineffective reperfusion” in which perfusion is restored when tissue was already fated to die 
(Table 1)11. Based on clinical trials, outcomes are improved only if thrombolytics are 
administered within a 6-hour window 6–8. Moreover, an analysis of IMS (Intervention 
Management of Stroke) patients demonstrated a time-dependent relationship between 
recanalization time and probability of good clinical outcome; the probability of good clinical 
outcome was greater than non-reperfused patients only if recanalization occured within 6 
hours of symptom onset38. Therefore, one might make the assumption that, on average, 6 
hours may represent the outside window for tissue viability (though it will likely vary from 
individual to individual).
Thus, in order to define brain tissue that falls within the ischemic penumbra, one must 
account for the reperfusion status of the brain tissue, and follow that tissue through time to 
determine its ultimate fate (death or survival). One approach that has been used to derive 
imaging thresholds that define the penumbra utilizes serial imaging to: 1) measure the 
imaging parameter of interest at baseline, 2) determine which tissue has reperfused within 
the viability window, and 3) determine which tissue eventually survives or dies. This 
imaging paradigm requires that acute ischemic stroke patients be imaged at three time-points 
(see Fig 1A). The earliest time-point (baseline) will acquire the quantitative imaging 
biomarker of interest. In addition, perfusion maps are acquired at this time-point. The 
second time-point, which will be acquired at the end of the presumptive tissue viability 
window (~6hrs), will identify regions of reperfusion (when compared to baseline perfusion 
maps). For this analysis, tissue-based reperfusion data (rather than recanalization) is 
required, as the reperfusion status of each voxel is needed for the final analysis. Finally, the 
third image will be acquired at 1–3 months after stroke to identify the region of final infarct 
(using FLAIR or T2 images), distinguishing tissue that survived from tissue that died. Co-
registration of images obtained at these three time-points will permit voxel-by-voxel 
analysis—each voxel carried forward through time will have an initial baseline quantitative 
value (imaging biomarker of interest), carry a history of reperfusion/nonreperfusion (within 
the first 6 hours), and a determination of eventual tissue fate (viable or infarcted). Because 
this analysis depends on reperfusion status (regardless of treatment with thrombolytics), data 
from both treated and untreated patients can be used.
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To determine the threshold for irreversible injury (tissue that dies regardless of reperfusion), 
brain regions that have reperfused are analyzed (Fig 1B, lower panel). Within this reperfused 
region, voxels that die will be segregated from voxels that survive, and the corresponding 
baseline value for the imaging biomarker of interest can be plotted in a frequency histogram 
(as shown in Fig 1C, lower panel). The threshold for irreversible injury will be the baseline 
value that best separates reperfused voxels that die from reperfused voxels that survive (Fig 
1C, lower panel, purple dashed line). This threshold value can be determined using a variety 
of statistical methods (e.g., the optimization of Youden’s index which maximizes sensitivity 
and specificity for prediction of tissue fate39). To determine the threshold for reversible 
injury, analysis is restricted to brain regions that have not reperfused (Fig 1B, upper panel). 
Voxels in these non-reperfused regions will be separated into tissue that survives 
(representing oligemic tissue) and tissue that dies (representing penumbral + core tissue). 
Thus, the baseline value that best separates voxels that die from those that survive represents 
the threshold for reversible injury (Fig 1C, upper panel, blue dashed line). Voxels (or brain 
tissue) with baseline values that fall between these two thresholds (for irreversible and 
reversible injury) represent the ischemic penumbra (Fig 1D).
As long as all three time-points are obtained, such an imaging analysis can be applied to 
virtually any quantitative imaging parameter (e.g. DWI-PWI mismatch, MR-OMI, etc.), to 
derive thresholds for reversible and irreversible injury based on reperfusion. Since the 
thresholds are derived on an individual-patient basis, a population-based average of each 
threshold must be obtained. The predictive performance of the population-derived thresholds 
(how well they predict tissue fate) can be subsequently tested in an independent population 
of patients (a different group of patients from which the thresholds were derived). 
Alternatively, the same patient population (from which the thresholds were derived) could 
serve as the “test” population, by using statistical re-sampling methods such as jackknifing, 
boot-strapping, or cross validation. The two thresholds will divide brain tissue into core, 
penumbra and oligemia, and their predictive value will be determined based on their ability 
to predict infarction or survival in reperfused and non-reperfused tissue as indicated in Table 
1. Thus, tissue determined to be in the core should have a high probability of infarction 
regardless of reperfusion; tissue in the penumbra will have high probability of infarction in 
the absence of reperfusion, but high probability of salvage with reperfusion; and finally, 
tissue categorized as oligemic will have a high probability of survival regardless of 
reperfusion5.
Several other computational methods to predict tissue outcome have been explored. Many of 
these methods have taken advantage of the multiparametric MR data collected during 
hyperacute stroke to create models that are highly predictive of tissue outcome. These 
approaches include voxel-by-voxel automated cluster analysis40, iterative self-organizing 
data analsyis (ISODATA) 41, and generalized linear modeling (GLM) 42. These predictive 
methods do not attempt to delineate the ischemic penumbra which requires knowledge of 
early reperfusion. Therefore, these approaches may have limited value in helping to guide 
acute management decisions. Indeed, the GLM approach has been shown to have lower 
predictive value in patients treated with thrombolysis compared to untreated patients43, 
reflecting the predictive nature of the models only in the absence of reperfusion.
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Regardless of method, once thresholds with high predictive value have been derived, the 
ultimate test of the imaging biomarker-derived threshold will be in therapeutic trials which 
utilize the imaging biomarker for patient selection.
Clinical studies testing penumbral imaging markers
Several clinical studies have been completed or are underway that have examined 
hyperacute neuro-imaging as a selection tool for therapy. These trials, which have 
specifically examined MR diffusion/perfusion mismatch (DPM), fall under three categories 
of study design: (1) one which utilizes DPM to select patients for enrollment in the 
therapeutic trial; these include studies such as Desmoteplase in Acute Ischemic Stroke trial 
(DIAS) 44, Dose Escalation for Ischemic Stroke trial (DEDAS) 45, and DIAS-II46; (2) one 
which aims to validate DPM as a biomarker of the penumbra, including studies such as 
Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution trial 
(DEFUSE) 47 and DEFUSE-2 48, 49; and (3) one which aims to do both such as Echoplanar 
Imaging Thrombolytic Evaluation Trial (EPITHET) 50 and Mechanical Recanalization of 
Stroke Clots Using Embolectomy study (MRRESCUE51).
These trials have demonstrated feasibility of testing an imaging biomarker as well as 
performing dual time-point imaging for measurement of reperfusion. The trials have also 
brought to light the importance of rigorous definition of ischemic thresholds. For example, 
DEFUSE was designed to validate DPM by comparing clinical outcomes in patients with 
DPM and reperfusion to patients without DPM and reperfusion; patients in both groups were 
treated with tPA between 3–6 hours of stroke onset 47. All patients were serially imaged 
with MRI prior to tPA treatment (to assess for the presence of mismatch), and at 3–6 hours 
after tPA treatment (to assess for tissue reperfusion). DWI lesions were defined as > 3 
standard deviations of the contralateral hemisphere and PWI lesions were defined as Tmax 
delay ≥ 2 sec. DPM was defined as PWI/DWI volume ≥ 1.2 and PWI-DWI volume ≥ 10 cc. 
Of 74 patients enrolled, after excluding patients with unsuccessful PWI scans or patients 
with a “small lesion profile”, 75% had DPM and 25% did not. In patients with DPM, 
reperfusion was associated with a significantly better clinical outcome than no reperfusion. 
However, due to the small number of patients without DPM (11 total), the converse (that 
non-mismatch patients did not improve with reperfusion) could not be proven, making it 
difficult to validate this penumbral imaging biomarker. The high ratio of mismatch to non-
mismatch patients made it clear that the definition for DPM was too liberal, resulting in a 
relatively unselected group of stroke patients, a subset of whom unlikely had salvageable 
tissue. Using similar DPM thresholds, the EPITHET trial also found that only 14% of 
patients had non-mismatch profiles 50.
Based on these results, the DEFUSE investigators refined the DPM definition, and this new 
profile was used in the DEFUSE-2 study. DWI lesions were defined as ADC < 600 mm2/sec 
and PWI lesions were defined as Tmax delay > 6 sec. DPM was defined as PWI/DWI≥1.8. 
However, beyond DPM, they selected a “target mismatch” group which excluded patients 
with very large baseline DWI (>70cc) and PWI (Tmax>10sec, >100cc) lesions since 
DEFUSE-1 indicated that these patients may have worse outcomes. The results of this study 
are forthcoming, but preliminary results look promising. Selection of patients with the 
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“target mismatch” definition demonstrated improved clinical outcome and reduced infarct 
growth compared to the non-target mismatch group 48, 49. The DEFUSE experience 
underscores the importance of rigorously defining the imaging biomarker for penumbra, and 
illustrates an opportunity to explore more quantitative approaches in doing so.
Conclusion
There is great promise that neuro-imaging may provide signatures that delineate the 
ischemic penumbra. However, to define this elusive and transient state during hyperacute 
cerebral ischemia will require rigorous study design. Critical to the definition of penumbra is 
the required knowledge of the reperfusion status of tissue, requiring multiple time-point 
imaging. Two thresholds are relevant to defining the penumbra: the first is a threshold that 
distinguishes core from penumbra, and the second distinguishes penumbra from benign 
oligemia. After validation of ischemic thresholds in an independent patient population, the 
imaging thresholds can then be tested in clinical trials which utilize the biomarkers for 
patient selection. Such rigorous testing will help to ensure that the imaging biomarker 
(whether DPM or another imaging parameter) truly has potential to identify salvageable 
tissue with reperfusion-promoting therapies.
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Figure 1. Defining Thresholds for a Penumbral Imaging Biomarker Based on Reperfusion
Baseline, 6 hr, and 1–3 month images are required to delineate baseline imaging values, 
reperfusion status, and final infarct. (B) Image co-registraton maps tissue reperfusion status 
and tissue fate (survival or death) on the baseline image and permits separate analysis of 
reperfused (lower panel) and non-reperfused (upper panel) tissue. (C) Frequency histograms 
of values of the baseline imaging biomarker are created from images in B. The baseline 
value which best separates surviving from dead tissue in non-reperfused regions (upper 
panel) marks the threshold of reversible injury (blue dashed line); while the baseline value 
which best separates surviving from dead tissue in reperfused regions (lower panel) marks 
the threshold of irreversible injury (purple dashed line). D. The penumbra falls between 
these two ischemic thresholds.
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